2012
DOI: 10.1111/j.1464-5491.2011.03520.x
|View full text |Cite
|
Sign up to set email alerts
|

QTc prolongation and diabetes therapies

Abstract: Diabet. Med. 29, 290–292 (2012)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 6 publications
0
2
0
Order By: Relevance
“…However, the number of patients with both neuropathy and ischemia were less in our study. Peripheral neuropathy is prevalent in type 2 diabetic patients, and these patients are far more likely to have complications or co-morbidities [ 21 ]. In our study, out of all patients with neuropathy, about 85% had moderate to severe intensity.…”
Section: Discussionmentioning
confidence: 99%
“…However, the number of patients with both neuropathy and ischemia were less in our study. Peripheral neuropathy is prevalent in type 2 diabetic patients, and these patients are far more likely to have complications or co-morbidities [ 21 ]. In our study, out of all patients with neuropathy, about 85% had moderate to severe intensity.…”
Section: Discussionmentioning
confidence: 99%
“…Given the lack of reliable estimates for the frequency of DSPN in different populations and the absence of clear diagnostic guidelines 17 , 18 , different clinical studies have been conducted by using various screening methods to identify DSPN 19 40 . QST, neuropathy disability score, Michigan neuropathy screening method, vibration sensing with a 128 Hz tuning fork, and monofilament test are used for assessing pain, touch, vibration, and temperature sensation loss due to DSPN 9 12 .…”
Section: Introductionmentioning
confidence: 99%